CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...